Alaunos Therapeutics Statistics
Total Valuation
TCRT has a market cap or net worth of $4.67 million. The enterprise value is $4.32 million.
| Market Cap | 4.67M |
| Enterprise Value | 4.32M |
Important Dates
The next estimated earnings date is Friday, August 21, 2026, after market close.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRT has 2.42 million shares outstanding. The number of shares has increased by 27.10% in one year.
| Current Share Class | 2.42M |
| Shares Outstanding | 2.42M |
| Shares Change (YoY) | +27.10% |
| Shares Change (QoQ) | -16.23% |
| Owned by Insiders (%) | 23.12% |
| Owned by Institutions (%) | 7.70% |
| Float | 1.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,558.25 |
| Forward PS | n/a |
| PB Ratio | 3.56 |
| P/TBV Ratio | 3.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,440.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63
| Current Ratio | 1.63 |
| Quick Ratio | 0.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -350.30% and return on invested capital (ROIC) is -220.85%.
| Return on Equity (ROE) | -350.30% |
| Return on Assets (ROA) | -129.43% |
| Return on Invested Capital (ROIC) | -220.85% |
| Return on Capital Employed (ROCE) | -321.82% |
| Weighted Average Cost of Capital (WACC) | -1.03% |
| Revenue Per Employee | $3,000 |
| Profits Per Employee | -$4.22M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.25% in the last 52 weeks. The beta is -0.96, so TCRT's price volatility has been lower than the market average.
| Beta (5Y) | -0.96 |
| 52-Week Price Change | -19.25% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 2.77 |
| Relative Strength Index (RSI) | 41.84 |
| Average Volume (20 Days) | 9,445 |
Short Selling Information
The latest short interest is 9,776, so 0.40% of the outstanding shares have been sold short.
| Short Interest | 9,776 |
| Short Previous Month | 13,319 |
| Short % of Shares Out | 0.40% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 0.76 |
Income Statement
In the last 12 months, TCRT had revenue of $3,000 and -$4.22 million in losses. Loss per share was -$2.07.
| Revenue | 3,000 |
| Gross Profit | -1.44M |
| Operating Income | -4.14M |
| Pretax Income | -4.11M |
| Net Income | -4.22M |
| EBITDA | -4.13M |
| EBIT | -4.14M |
| Loss Per Share | -$2.07 |
Balance Sheet
The company has $354,000 in cash and no debt, with a net cash position of $354,000 or $0.15 per share.
| Cash & Cash Equivalents | 354,000 |
| Total Debt | n/a |
| Net Cash | 354,000 |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 1.29M |
| Book Value Per Share | 0.54 |
| Working Capital | 375,000 |
Cash Flow
In the last 12 months, operating cash flow was -$3.13 million and capital expenditures -$98,000, giving a free cash flow of -$3.23 million.
| Operating Cash Flow | -3.13M |
| Capital Expenditures | -98,000 |
| Depreciation & Amortization | 14,500 |
| Net Borrowing | n/a |
| Free Cash Flow | -3.23M |
| FCF Per Share | -$1.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | -138,166.67% |
| Pretax Margin | -136,966.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.10% |
| Shareholder Yield | -27.10% |
| Earnings Yield | -90.17% |
| FCF Yield | -69.01% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 18, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
TCRT has an Altman Z-Score of -688.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -688.96 |
| Piotroski F-Score | 2 |